Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 26Rectal Neoplasms 6Colonic Neoplasms 6Neoplasm Metastasis 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Advanced Solid Tumors 3Stomach Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Advanced Solid Tumors (Excluding Breast Cancer) 2Urologic Diseases 1Solid Tumor Cancer 1Renal Insufficiency 1Refractory Solid Tumors 1Pretreated Metastatic Colorectal Cancer 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 124Cisplatin 27lenvatinib 24Carboplatin 24Paclitaxel 19Docetaxel 16Fluorouracil 13Capecitabine 11Pemetrexed 10Gemcitabine 10Saline Solution 8Oxaliplatin 8epacadostat 6Leucovorin 5Irinotecan 5Cetuximab 5olaparib 4Bevacizumab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3regorafenib 3enzalutamide 3durvalumab 3Nivolumab 3Etoposide 3trametinib 2etoposide phosphate 2dabrafenib 2Tretinoin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × trifluridine tipiracil drug combination × Clear all
NCT05064059 2026-05-26

MK-4280A-007

Merck Sharp & Dohme LLC

Phase 3 Completed
441 enrolled 24 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Merck Sharp & Dohme LLC

Phase 3 Completed
563 enrolled 32 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Merck Sharp & Dohme LLC

Phase 3 Completed
94 enrolled 15 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡